Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 1 May 2007. doi:10.1136/ard.2006.062919
Annals of the Rheumatic Diseases 2007;66:1450-1455
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism.

EXTENDED REPORTS

Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis

Marja-Kaisa Koivula1, Markku Heliövaara3, Jarmo Ramberg2, Paul Knekt3, Harri Rissanen3, Timo Palosuo3, Juha Risteli2

1 Departments of Clinical Chemistry, University of Oulu and University of Turku, Oulu and Turku, Finland
2 Department of Clinical Chemistry, University of Oulu, Oulu, Finland
3 National Public Health Institute, Helsinki, Finland

Juha Risteli, MD, PhD, Professor of Clinical Chemistry, University of Oulu, PO Box 5000, FI-90014 University of Oulu, Finland; juha.risteli{at}oulu.fi

Objectives: To find out whether autoantibodies to citrullinated telopeptides of type I and II collagens and to cyclic citrullinated peptides (CCPs) predict the development of rheumatoid arthritis (RA).

Methods: A case-control study (matched for sex, age and municipality) was nested within a Finnish cohort of 19072 adults who had neither arthritis nor a history of it at the baseline examination during 1973–7. 124 subjects developed RA by late 1989, and of these, 89 were positive for rheumatoid factor (RF). Preillness serum specimens were analysed for autoantibodies against arginine (A)- or citrulline (C)-containing synthetic telopeptides using a chemiluminescence method and for anti-CCPs Mark2 with an enzyme-linked immunosorbent assay method.

Results: The mean levels of autoantibodies to citrulline-containing telopeptides and the C/A ratios of type I and II collagens and to CCP were higher in subjects who later developed RF-positive RA. In the highest tertiles of C/A (I), C/A (II) ratios and anti-CCPs levels, the relative risk of RF-positive RA was significantly increased. In the multifactorial model, only anti-CCPs retained its statistical significance. However, the interaction term of C/A (II) ratio and anti-CCPs proved to be statistically significant (p = 0.02). The subjects ranked into the highest tertiles of both C/A (II) ratio and anti-CCPs had an odds ratio of 20.06 (95% confidence interval, 4.37 to 92.06) of developing RF-positive RA compared with those in the lowest tertiles of these antibodies. None of the autoantibodies predicted RF-negative RA.

Conclusion: Autoantibodies to citrullinated telopeptides of type I and II collagen and to CCPs exert a synergistic effect on the risk of seropositive RA.

Abbreviations: CCP, cyclic citrullinated peptide; ELISA, enzyme-linked immunosorbent assay; PAD, peptidylarginine deiminase; RA, rheumatoid arthritis; RF, rheumatoid factor


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Koivula, M.-K., Savolainen, E., Kaipiainen-Seppanen, O., Kautiainen, H., Luosujarvi, R., Hakala, M., Risteli, J. (2008). Sensitivity and specificity of autoantibodies binding to citrullinated carboxyterminal telopeptides of types I and II collagens in an early arthritis series. Rheumatology (Oxford) 47: 656-659 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs